Ex-Juno execs reportedly seeking up to $1B for new biotech startup

Former Juno Therapeutics Inc. executives Hans Bishop and Steve Harr have co-founded a new biotech, Sana Biotechnology Inc., less than a year after leading Juno through a $9 billion acquisition by Celgene Corp......»»

Category: topSource: bizjournalsJan 11th, 2019

Pennovation Center-based biotech startup raises $13M

The company, led by two former Janssen Pharmaceutical execs, is seeking to commercialize a new protein drug platform based on technology licensed from Johnson & Johnson......»»

Category: topSource: bizjournalsDec 11th, 2018

Juno Therapeutics and investors reach settlement related to fatal drug trial

The $24 million mediated settlement stems from a string of patient deaths that nearly derailed Seattle's star biotech startup two years ago......»»

Category: topSource: bizjournalsSep 2nd, 2018

This cancer-fighting biotech sped from startup to IPO filing in 10 months

The team that took Kite Pharma from a startup re-engineering a patient's own cells to fight cancer to a $12 billion buyout now is seeking a $100 million initial public offering for the South San Francisco company it launched only 10 months ago. Arie B.....»»

Category: topSource: bizjournalsSep 17th, 2018

Controversial Startup Moderna Just Filed for the Biggest Biotech IPO Ever

The unicorn is seeking to raise a staggering $500 million, despite having no products on the market. Moderna Therapeutics just filed for what wo.....»»

Category: europeSource: fortuneNov 9th, 2018

Ex-Juno execs lease more than 30,000 square feet in Lake Union life science building

The 198,000-square-foot "Atrium" building is now 49 percent leased with three biotech tenants......»»

Category: topSource: bizjournalsFeb 5th, 2019

NeuBase stock drops 15% in first day of trading

Pittsburgh’s newest public company lost 84 cents by the end of trading on Monday. Shares of NeuBase Therapeutics Inc. closed at $4.55 per share, down 15.58%. The biotech company was created through the reverse merger of NeuBase, a startup bas.....»»

Category: topSource: bizjournalsJul 16th, 2019

Genmab IPO: What You Need To Know

An OTC-listed large-cap biotech is seeking a main exchange listing, and it offers scope for investing in a proven biotech with two commercial partnered products on the market and more in the pipeline. read more.....»»

Category: blogSource: benzingaJul 15th, 2019

Treasury Curve "Kink" Signals Debt-Ceiling Anxiety Is Accelerating

Treasury Secretary Steven Mnuchin is reportedly seeking to arrange another budget and debt ceiling meeting with House Speaker Nancy Pelosi, according to Senate Appropriations Chairman Richard Shelby. Perhaps Mr. Mnuc.....»»

Category: blogSource: zerohedgeJul 10th, 2019

Launch NY still seeking local investors for its new startup funding program

Launch NY is still seeking beta testers for its "Investor Network," a digital networking tool that helps accredited investors source startup deals. The nonprofit has about 50 of the 100 early adopters it is seeking for the network and is extendin.....»»

Category: topSource: bizjournalsJul 10th, 2019

With new execs on board, Celsius signs Janssen deal

A year after launching, Third Rock Ventures-backed startup Celsius Therapeutics is set to begin working with one of the pharmaceutical industry’s biggest players to analyze the microscopic reactions that occur when a person ingests a drug......»»

Category: topSource: bizjournalsJul 9th, 2019

Genentech, Roche vets aim new company"s $86.25 million IPO at cancer

A South San Francisco startup led by veterans of biotech stalwart Genentech Inc. and its parent company Roche wants to raise $86.25 million in an initial public offering. RAPT Therapeutics Inc. — known until May as FLX Bio Inc. — expects to us.....»»

Category: topSource: bizjournalsJul 5th, 2019

After reportedly laying off 20% of its staff amid dwindling downloads, HQ Trivia is about to try something new

HQ Trivia HQ Trivia has reportedly laid off about 20% of its staff, leaving the live game show startup with less than 30 employees. Downloads .....»»

Category: topSource: businessinsiderJul 5th, 2019

Golem Execs Depart to Pursue ‘Riskier’ Research With New Non-Profit

Two executives from Golem Factory are leaving the startup to head up a new non-profit R&D effort......»»

Category: forexSource: coindeskJun 28th, 2019

Apple reportedly acquires self-driving startup

iPhone maker has acquired the startup's assets and hired many of its engineers, Axios reports......»»

Category: topSource: moneycentralJun 26th, 2019

Fast-growing dog food startup takes Greenwich Village office

Home-cooked dog food service The Farmer's Dog is reportedly moving to a new office in Greenwich Village. The Commercial Observer reports that the startup has signed a 2.5-year sublease for 19,000... To view the full story, click the title link......»»

Category: blogSource: crainsnewyorkJun 24th, 2019

Undeterred by Vertex"s plans, biotech Dyne enters Duchenne drug fray

The field of biotechs developing treatments for Duchenne muscular dystrophy became more crowded this week, with biotech startup Dyne setting its sights on the muscle-wasting rare disease......»»

Category: topSource: bizjournalsJun 13th, 2019

New Jersey biotech firm scales back Lake Nona plans

The company reportedly considered other cities for a new facility, but the Orlando City Council approved a nearly $380,000 incentive deal Aug. 20 to attract it to Central Florida......»»

Category: topSource: bizjournalsJun 12th, 2019

Amid IPO rumors, this biotech unicorn taps ex-Juno CEO to lead company

The former site head of Bayer's Berkeley campus is taking over as CEO of Menlo Park, California-based Grail Inc., which has raised close to $2 billion to develop a simple blood test aimed at detecting cancer early. Hans Bishop, who led Seattle-ba.....»»

Category: topSource: bizjournalsJun 11th, 2019

Merck snaps up preclinical Lexington biotech for up to $773M

Tilos Therapeutics, a quiet preclinical biotech developing treatments for cancer and autoimmune diseases, has become the latest startup to be acquired by pharmaceutical giant Merck & Co. Merck (NYSE: MRK) announced Monday that it has agreed to pay up.....»»

Category: topSource: bizjournalsJun 10th, 2019

Vertex enters Duchenne field with $245M buy of Exonics

Biotech giant Vertex Pharmaceuticals announced plans Thursday to acquire a Cambridge-based preclinical gene editing startup, giving a run for the money to fellow Cambridge drugmaker Sarepta Therapeutics and others developers of drugs for Duchenne m.....»»

Category: topSource: bizjournalsJun 6th, 2019